Project Grant R44NS147802
Award Date 7/14/26
Completion Date 6/30/28
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Brooklyn, NY 11215, USA
Similar Awards
- Federal Grant Award Summary Janusq LLC received a $490,501 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on September 15, 2025, with completion targeted for February 28, 2027. The startup biotechnology company is developing HV-3, a peptide-based therapeutic candidate designed to treat mitochondrial dysfunction associated with...
- Federal Project Grant Award Summary Biostrategies LC received a $1,558,305 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 15, 2025, with completion targeted for August 30, 2027. The award funds completion of Investigational New Drug (IND)-enabling studies for BIOS-GM1, a novel therapeutic combining gene therapy with enzyme...
- Federal Grant Award Summary Neurogt Inc. received a Phase II Small Business Innovation Research (SBIR) Project Grant of $722,587 awarded on September 16, 2025, by the National Institutes of Health Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to develop and commercialize an adeno-associated virus 9 (AAV9) gene replacement therapy for treating Mucopolysaccharidosis (MPS) I, specifically targeting central nervous system neuropathy associated with MPS IH (Hurler...
- FEDERAL GRANT AWARD SUMMARY Cincinnati Children's Hospital Medical Center received a $803,958 Project Grant award (announced July 23, 2025) from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award supports research and development of an innovative nanocarrier-based therapeutic delivery system designed to treat neuronopathic Gaucher disease (NGD), a severe...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant of $221,400 (obligated August 1, 2025) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The five-year award (through July 31, 2030) funds research investigating the role of the c-Jun N-terminal kinase (JNK) signaling pathway in neurodevelopmental disorders...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $2.66 million to The Regents of the University of California, San Francisco under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate delivery vectors for central nervous system (CNS) gene therapies and biologics. The five-year project grant, awarded February 15, 2026 and extending through January 31, 2031,...
- Federal Grant Award Summary Epicure Therapeutics, Inc. received a $1.5M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 16, 2026, with completion targeted for June 30, 2028. The company is developing a cell class-specific adeno-associated virus (AAV) gene therapy targeting SLC6A1-related neurodevelopmental disorder, a severe...
- Federal Project Grant Award Summary Galibra Neuroscience, Inc. received a $500,000 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded September 1, 2025, with completion expected August 31, 2026. The award supports the development of a brain-penetrable adeno-associated virus (AAV) gene therapy designated GAL005 for the treatment of succinic...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Scripps Research Institute a Project Grant of $710,155 on February 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The five-year award, extending through January 31, 2031, supports research into post-transcriptional mechanisms governing cortical inhibitory interneuron (CIN) development. The project delivers basic...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $404,282 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 1, 2026, with completion anticipated by April 30, 2028. The award supports the development of novel adeno-associated virus (AAV) capsids engineered to evade pre-existing neutralizing antibodies while...